The European multicentre bronchiectasis audit and research collaboration (EMBARC)

Experiences from a successful ERS clinical research collaboration

James D. Chalmers, Megan Crichton, Pieter C. Goeminne, Michael R. Loebinger, Charles Haworth, Marta Almagro, Montse Vendrell, Anthony De Soyza, Raja Dhar, Lucy Morgan, Francesco Blasi, Stefano Aliberti, Jeanette Boyd, Eva Polverino, EMBARC, the European Lung Foundation (ELF) and the EMBARC/ELF patient advisory group

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

In contrast to airway diseases like chronic obstructive pulmonary disease or asthma, and rare diseases such as cystic fibrosis, there has been little research and few clinical trials in bronchiectasis. Guidelines are primarily based on expert opinion and treatment is challenging because of the heterogeneous nature of the disease. In an effort to address decades of underinvestment in bronchiectasis research, education and clinical care, the European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC) was established in 2012 as a collaborative pan-European network to bring together bronchiectasis researchers. The European Respiratory Society officially funded EMBARC in 2013 as a Clinical Research Collaboration, providing support and infrastructure to allow the project to grow. EMBARC has now established an international bronchiectasis registry that is active in more than 30 countries both within and outside Europe. Beyond the registry, the network participates in designing and facilitating clinical trials, has set international research priorities, promotes education and has participated in producing the first international bronchiectasis guidelines. This manuscript article the development, structure and achievements of EMBARC from 2012 to 2017.

Original languageEnglish
Pages (from-to)180-192
Number of pages13
JournalBreathe
Volume13
Issue number3
DOIs
Publication statusPublished - Sep 1 2017

Fingerprint

Bronchiectasis
Research
Registries
Clinical Trials
Guidelines
Education
Expert Testimony
Rare Diseases
Cystic Fibrosis
Chronic Obstructive Pulmonary Disease
Asthma
Research Personnel

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Chalmers, J. D., Crichton, M., Goeminne, P. C., Loebinger, M. R., Haworth, C., Almagro, M., ... EMBARC, the European Lung Foundation (ELF) and the EMBARC/ELF patient advisory group (2017). The European multicentre bronchiectasis audit and research collaboration (EMBARC): Experiences from a successful ERS clinical research collaboration. Breathe, 13(3), 180-192. https://doi.org/10.1183/20734735.005117

The European multicentre bronchiectasis audit and research collaboration (EMBARC) : Experiences from a successful ERS clinical research collaboration. / Chalmers, James D.; Crichton, Megan; Goeminne, Pieter C.; Loebinger, Michael R.; Haworth, Charles; Almagro, Marta; Vendrell, Montse; De Soyza, Anthony; Dhar, Raja; Morgan, Lucy; Blasi, Francesco; Aliberti, Stefano; Boyd, Jeanette; Polverino, Eva; EMBARC, the European Lung Foundation (ELF) and the EMBARC/ELF patient advisory group.

In: Breathe, Vol. 13, No. 3, 01.09.2017, p. 180-192.

Research output: Contribution to journalArticle

Chalmers, JD, Crichton, M, Goeminne, PC, Loebinger, MR, Haworth, C, Almagro, M, Vendrell, M, De Soyza, A, Dhar, R, Morgan, L, Blasi, F, Aliberti, S, Boyd, J, Polverino, E & EMBARC, the European Lung Foundation (ELF) and the EMBARC/ELF patient advisory group 2017, 'The European multicentre bronchiectasis audit and research collaboration (EMBARC): Experiences from a successful ERS clinical research collaboration', Breathe, vol. 13, no. 3, pp. 180-192. https://doi.org/10.1183/20734735.005117
Chalmers, James D. ; Crichton, Megan ; Goeminne, Pieter C. ; Loebinger, Michael R. ; Haworth, Charles ; Almagro, Marta ; Vendrell, Montse ; De Soyza, Anthony ; Dhar, Raja ; Morgan, Lucy ; Blasi, Francesco ; Aliberti, Stefano ; Boyd, Jeanette ; Polverino, Eva ; EMBARC, the European Lung Foundation (ELF) and the EMBARC/ELF patient advisory group. / The European multicentre bronchiectasis audit and research collaboration (EMBARC) : Experiences from a successful ERS clinical research collaboration. In: Breathe. 2017 ; Vol. 13, No. 3. pp. 180-192.
@article{0abe9b8fbe1b4f2ba705572928915f25,
title = "The European multicentre bronchiectasis audit and research collaboration (EMBARC): Experiences from a successful ERS clinical research collaboration",
abstract = "In contrast to airway diseases like chronic obstructive pulmonary disease or asthma, and rare diseases such as cystic fibrosis, there has been little research and few clinical trials in bronchiectasis. Guidelines are primarily based on expert opinion and treatment is challenging because of the heterogeneous nature of the disease. In an effort to address decades of underinvestment in bronchiectasis research, education and clinical care, the European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC) was established in 2012 as a collaborative pan-European network to bring together bronchiectasis researchers. The European Respiratory Society officially funded EMBARC in 2013 as a Clinical Research Collaboration, providing support and infrastructure to allow the project to grow. EMBARC has now established an international bronchiectasis registry that is active in more than 30 countries both within and outside Europe. Beyond the registry, the network participates in designing and facilitating clinical trials, has set international research priorities, promotes education and has participated in producing the first international bronchiectasis guidelines. This manuscript article the development, structure and achievements of EMBARC from 2012 to 2017.",
author = "Chalmers, {James D.} and Megan Crichton and Goeminne, {Pieter C.} and Loebinger, {Michael R.} and Charles Haworth and Marta Almagro and Montse Vendrell and {De Soyza}, Anthony and Raja Dhar and Lucy Morgan and Francesco Blasi and Stefano Aliberti and Jeanette Boyd and Eva Polverino and {EMBARC, the European Lung Foundation (ELF) and the EMBARC/ELF patient advisory group}",
year = "2017",
month = "9",
day = "1",
doi = "10.1183/20734735.005117",
language = "English",
volume = "13",
pages = "180--192",
journal = "Breathe",
issn = "1810-6838",
publisher = "European Respiratory Society",
number = "3",

}

TY - JOUR

T1 - The European multicentre bronchiectasis audit and research collaboration (EMBARC)

T2 - Experiences from a successful ERS clinical research collaboration

AU - Chalmers, James D.

AU - Crichton, Megan

AU - Goeminne, Pieter C.

AU - Loebinger, Michael R.

AU - Haworth, Charles

AU - Almagro, Marta

AU - Vendrell, Montse

AU - De Soyza, Anthony

AU - Dhar, Raja

AU - Morgan, Lucy

AU - Blasi, Francesco

AU - Aliberti, Stefano

AU - Boyd, Jeanette

AU - Polverino, Eva

AU - EMBARC, the European Lung Foundation (ELF) and the EMBARC/ELF patient advisory group

PY - 2017/9/1

Y1 - 2017/9/1

N2 - In contrast to airway diseases like chronic obstructive pulmonary disease or asthma, and rare diseases such as cystic fibrosis, there has been little research and few clinical trials in bronchiectasis. Guidelines are primarily based on expert opinion and treatment is challenging because of the heterogeneous nature of the disease. In an effort to address decades of underinvestment in bronchiectasis research, education and clinical care, the European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC) was established in 2012 as a collaborative pan-European network to bring together bronchiectasis researchers. The European Respiratory Society officially funded EMBARC in 2013 as a Clinical Research Collaboration, providing support and infrastructure to allow the project to grow. EMBARC has now established an international bronchiectasis registry that is active in more than 30 countries both within and outside Europe. Beyond the registry, the network participates in designing and facilitating clinical trials, has set international research priorities, promotes education and has participated in producing the first international bronchiectasis guidelines. This manuscript article the development, structure and achievements of EMBARC from 2012 to 2017.

AB - In contrast to airway diseases like chronic obstructive pulmonary disease or asthma, and rare diseases such as cystic fibrosis, there has been little research and few clinical trials in bronchiectasis. Guidelines are primarily based on expert opinion and treatment is challenging because of the heterogeneous nature of the disease. In an effort to address decades of underinvestment in bronchiectasis research, education and clinical care, the European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC) was established in 2012 as a collaborative pan-European network to bring together bronchiectasis researchers. The European Respiratory Society officially funded EMBARC in 2013 as a Clinical Research Collaboration, providing support and infrastructure to allow the project to grow. EMBARC has now established an international bronchiectasis registry that is active in more than 30 countries both within and outside Europe. Beyond the registry, the network participates in designing and facilitating clinical trials, has set international research priorities, promotes education and has participated in producing the first international bronchiectasis guidelines. This manuscript article the development, structure and achievements of EMBARC from 2012 to 2017.

UR - http://www.scopus.com/inward/record.url?scp=85035811855&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85035811855&partnerID=8YFLogxK

U2 - 10.1183/20734735.005117

DO - 10.1183/20734735.005117

M3 - Article

VL - 13

SP - 180

EP - 192

JO - Breathe

JF - Breathe

SN - 1810-6838

IS - 3

ER -